Industry | 2010.02.01
SDI Selected Again to Produce Monoclonal Antibodies for SAIC-F to Advance Cancer Research
NEWARK, Del.--(BUSINESS WIRE)--SDI (Strategic Diagnostics Inc., NASDAQ:SDIX), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, today announced it has been selected again by Science Applications International Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute’s “Clinical Proteomic Technologies for Cancer” initiative (CPTC: http://proteomics
For more information, please visit
http://www.businesswire.com/news/home/20100201005220/en
